Valeant Pharmaceuticals (VRX) expects its 2012 earnings to be at the upper end of its predicted...

|About: Valeant Pharmaceuticals I... (VRX)|By:, SA News Editor

Valeant Pharmaceuticals (VRX) expects its 2012 earnings to be at the upper end of its predicted ranges of $4.45-$4.70 for EPS and $3.4B-$3.6B for revenues. The guidance doesn't include recently announced acquisitions such as Natur Produkt, Acne Free, Swiss Herbal Life and OraPharma. Valeant is holding its investor day today. (PR)